Systemic Lupus Erythematosus Symptoms - Articles

Sort by: Newest Most Comments Relevance

Systemic lupus erythematosus (SLE) by Ahmad.H Posted Fri 03 Dec 2010 12:00am SLE is a chronic disease that causes inflammation of connective tissue. It is a multisystem autoimmune inflammatory disease. SLE is the commonest and the most serious type of lupus. What causes SLE ? SLE is believed to be an autoimmune disease, which means that the body's immune system produce antibodies that attacks the own ... Read on »

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE) by Duane P. Patient Expert

Posted Mon 31 Aug 2009 10:08pm

1 Comment with systemic lupus. The data showed that the 12-week dose response and the dose frequency study of epratuzumab in patients with moderate to severe active lupus demonstrated a clinically meaningful treatment effect showing the drug was more effective than placebo in reducing symptoms of lupus. “The LFA congratulates UCB and Immunomedics on the positive results from Read on »

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE) by Wick D. Posted Mon 31 Aug 2009 6:58am with systemic lupus. The data showed that the 12-week dose response and the dose frequency study of epratuzumab in patients with moderate to severe active lupus demonstrated a clinically meaningful treatment effect showing the drug was more effective than placebo in reducing symptoms of lupus. “The LFA congratulates UCB and Immunomedics on the positive results from Read on »

Sicca symptoms in Thai patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma: a comparison with age-m by Jan Posted Fri 11 Sep 2009 4:58pm (RA), systemic lupus erythematosus (SLE), and scleroderma (Scl). The ocular symptoms and sign (the Schirmer's 1 test) and the oral sicca symptoms and sign (the Saxon's test) in each of 50 RA, SLE and Scl patients were compared with their age-matched controls. The correlation between the presence of sicca symptoms and signs with their clinical activity Read on »

OxLDL/β2GPI Complexes and Autoantibodies in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, and Antiphospho by Jan Posted Fri 11 Sep 2009 4:56pm immunosorbent assay (ELISA). Measurements were taken in two patient groups: (1) those with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and rheumatoid arthritis (RA); and (2) those with primary and secondary antiphospholipid syndrome (APS). For oxLDL/β2GPI complexes, SLE and SSc patients had the highest mean optical densities (ODs) ( P Read on »

OxLDL/β2GPI Complexes and Autoantibodies in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, and Antiphospho by Jan Posted Fri 11 Sep 2009 4:56pm assay (ELISA). Measurements were taken in two patient groups: (1) those with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and rheumatoid arthritis (RA); and (2) those with primary and secondary antiphospholipid syndrome (APS). For oxLDL/β2GPI complexes, SLE and SSc patients had the highest mean optical densities (ODs) ( P < .001 Read on »

Anxiety News: Anxiety And Depression Lower Quality Of Life In Majority Of Systemic Lupus Erythematosus Patients by Katie G. Healthy Living Professional

Posted Wed 17 Jun 2009 6:31pm Anxiety And Depression Lower Quality Of Life In Majority Of Systemic Lupus Erythematosus Patients ScienceDaily (June 12, 2009) — 92.8% of patients with systemic lupus erythematosus (SLE) suffer anxiety and depression which significantly affects both their physical and emotional quality of life (QoL), according to the results of a new study presented Read on »

New Data Shows Epratuzumab Provided Significant Efficacy for Patients with Moderate to Severe Systemic Lupus Erythematosus by Duane P. Patient Expert

Posted Wed 16 Jun 2010 9:02am UCB and Immunomedics Inc. announced today that a new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Findings demonstrate that in a patient population with predominantly severe disease activity, epratuzumab is improving patients Read on »

New Data Shows Epratuzumab Provided Significant Efficacy for Patients with Moderate to Severe Systemic Lupus Erythematosus by Wick D. Posted Wed 16 Jun 2010 12:10pm UCB and Immunomedics Inc. announced today that a new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Findings demonstrate that in a patient population with predominantly severe disease activity, epratuzumab is improving Read on »

Systemic sclerosis (scleroderma) associated with discoid lupus erythematosus. by Jan Posted Sun 29 Aug 2010 12:00am had DLE on the face and extremities. No case fulfilled criteria for systemic lupus erythematosus (SLE). The present cases with SS and DLE, but without SLE, indicate... Six patients with systemic sclerosis (SS) and discoid lupus erythematosus (DLE) were studied to determine whether such cases have some common clinical and laboratory Read on »